Assessing Eligibility for Cardiovascular-Kidney-Metabolic Therapies in US Adults

Novel cardiovascular-kidney-metabolic (CKM) therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter-2 inhibitors (SGLT2is), and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), continue to show expanding indications for patients with obesity and associated cardiometabolic and renal risk factors. This quiz will assess your understanding of how common FDA-approved indications for these therapies are among US adults, based on findings from national surveys, community-based, and ambulatory healthcare samples.